Germany's Rhön-Klinikum 2025 revenue rises on patient growth

Rhoen Klinikum AG

26/03/2026 13:29

Overview

Germany healthcare provider's 2025 revenue grew 6.8%, beating analyst expectations

Net income for 2025 declined due to higher depreciation and impairment costs

Company expects 2026 revenue around EUR 1.7 bln plus or minus 5%, with EBITDA EUR 110-125 mln

Outlook

Company expects 2026 revenue of EUR 1.7 bln, plus or minus 5%

Company forecasts 2026 EBITDA between EUR 110 mln and EUR 125 mln

Company sees moderate increase in number of cases and cost weights in 2026

Result Drivers

PATIENT GROWTH - Co said revenue increase was driven by a 2.8% rise in patients treated across clinics and care centers

MEDICAL TECHNOLOGY INVESTMENT - Co cited investments in high-tech medical equipment and facility upgrades as supporting growth

HIGHER COSTS - Co said profit declined due to higher depreciation, impairment of fixed assets, and increased personnel and medical product expenses

Company press release: ID:nEQ93Vnh9a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
EUR 1.70 bln
EUR 1.66 bln (3 Analysts)
FY Net Income
EUR 36.30 mln
FY EBITDA
EUR 105.90 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Rhoen Klinikum AG is €14.00, about 12% above its March 25 closing price of €12.50

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)